Form 4: Aryeh Jason sold LGND
Aryeh Jason (Director at LIGAND PHARMACEUTICALS INC) reported an open-market sale of 3,000 shares of LGND at an average $320.05, roughly $960,141, in a Form 4 filed 2026-11-12.
Past performance does not predict future results. Informational only, not investment advice.
Aryeh Jason (Director at LIGAND PHARMACEUTICALS INC) reported an open-market sale of 3,000 shares of LGND at an average $320.05, roughly $960,141, in a Form 4 filed 2026-11-12.
Aryeh Jason (Director at LIGAND PHARMACEUTICALS INC) reported an open-market sale of 2,111 shares of LGND at an average $320.30, roughly $676,158, in a Form 4 filed 2026-11-03.
Zimmermann Martine (Director at LIGAND PHARMACEUTICALS INC) reported an open-market sale of 1,200 shares of LGND at an average $285.00, roughly $342,000, in a Form 4 filed 2026-09-14.
Haas Jason (Director at LIGAND PHARMACEUTICALS INC) reported an open-market sale of 7,138 shares of LGND at an average $292.81, roughly $2,090,062, in a Form 4 filed 2026-08-14.
End of results.